IL237604B - Compositions of enzalutamide - Google Patents

Compositions of enzalutamide

Info

Publication number
IL237604B
IL237604B IL237604A IL23760415A IL237604B IL 237604 B IL237604 B IL 237604B IL 237604 A IL237604 A IL 237604A IL 23760415 A IL23760415 A IL 23760415A IL 237604 B IL237604 B IL 237604B
Authority
IL
Israel
Prior art keywords
enzalutamide
formulations
Prior art date
Application number
IL237604A
Other languages
English (en)
Hebrew (he)
Other versions
IL237604A0 (en
Original Assignee
Medivation Prostate Therapeutics Llc
Astellas Pharma Inc
Bend Res Inc
Medivation Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL237604(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, Astellas Pharma Inc, Bend Res Inc, Medivation Llc filed Critical Medivation Prostate Therapeutics Llc
Publication of IL237604A0 publication Critical patent/IL237604A0/en
Publication of IL237604B publication Critical patent/IL237604B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL237604A 2012-09-11 2015-03-08 Compositions of enzalutamide IL237604B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11
PCT/US2013/059223 WO2014043208A1 (en) 2012-09-11 2013-09-11 Formulations of enzalutamide

Publications (2)

Publication Number Publication Date
IL237604A0 IL237604A0 (en) 2015-04-30
IL237604B true IL237604B (en) 2021-07-29

Family

ID=49231627

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237604A IL237604B (en) 2012-09-11 2015-03-08 Compositions of enzalutamide

Country Status (30)

Country Link
US (11) US20140100256A1 (https=)
EP (6) EP2895463A1 (https=)
JP (5) JP6404217B2 (https=)
KR (1) KR102225416B1 (https=)
CN (2) CN109897004A (https=)
AU (2) AU2013315619B2 (https=)
BR (1) BR112015005432B1 (https=)
CA (1) CA2884795C (https=)
CY (1) CY1124729T1 (https=)
DK (1) DK3725778T4 (https=)
EA (2) EA033374B9 (https=)
ES (1) ES2892029T5 (https=)
FI (1) FI3725778T4 (https=)
HK (1) HK1212701A1 (https=)
HR (1) HRP20211423T4 (https=)
HU (1) HUE057701T2 (https=)
IL (1) IL237604B (https=)
IN (1) IN2015DN02875A (https=)
LT (1) LT3725778T (https=)
MX (3) MX363974B (https=)
PH (1) PH12015500525A1 (https=)
PL (1) PL3725778T5 (https=)
PT (1) PT3725778T (https=)
RS (1) RS62676B2 (https=)
SI (1) SI3725778T1 (https=)
SM (1) SMT202100550T1 (https=)
TW (1) TWI673051B (https=)
UA (1) UA117353C2 (https=)
WO (1) WO2014043208A1 (https=)
ZA (1) ZA201501847B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN105377299B (zh) * 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
LT3226842T (lt) * 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
HUE054935T2 (hu) * 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
US20180022819A1 (en) * 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
WO2017027665A1 (en) 2015-08-12 2017-02-16 Medivation Prostate Therapeutics, Inc. Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
US11478453B2 (en) 2016-07-21 2022-10-25 Hadasit Medical Research Services And Development Ltd. Treatment for glioblastoma
CA3036011A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
KR102640668B1 (ko) * 2017-04-13 2024-02-23 장 폴 레몬 잔토휴몰-계 조성물
JP7172997B2 (ja) * 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
BR112020002705A2 (pt) * 2017-08-08 2020-07-28 Dr. Reddys Laboratories Limited composições extrudadas de enzalutamida
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
WO2020122244A1 (ja) * 2018-12-14 2020-06-18 富士フイルム株式会社 錠剤及びその製造方法
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
CA3139380A1 (en) 2019-05-16 2020-11-19 Leon-Nanodrugs Gmbh Method for producing nanoparticles
CA3141534A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220242829A1 (en) 2019-06-27 2022-08-04 Synthon B.V. Process for preparation of enzalutamide
JP7812785B2 (ja) * 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
CA3149182A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
WO2021064123A1 (en) 2019-10-03 2021-04-08 Synthon B.V. Pharmaceutical composition comprising enzalutamide
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
IL297939A (en) * 2020-05-06 2023-01-01 Disruptive Pharma Ab New amorphous active pharmaceutical ingredients
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN114053243B (zh) * 2020-08-05 2024-11-12 齐鲁制药有限公司 一种恩扎卢胺软胶囊及其制备方法
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
CA3191084A1 (en) * 2020-09-09 2022-03-17 Gerald Burke Formulations of a somatostatin modulator
IL301389A (en) * 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
BR112023022789A2 (pt) 2021-07-07 2024-02-27 Bdr Pharmaceuticals International Private Ltd Composição farmacêutica na forma de uma solução oral de enzalutamida, composição farmacêutica na forma de uma solução oral de enzalutamida e método para preparar uma solução oral de enzalutamida
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
CN118251213A (zh) * 2022-01-19 2024-06-25 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide
WO2024191660A2 (en) * 2023-03-10 2024-09-19 Yale University Compositions and methods for treating steroid hormone-related diseases or disorders
CN121038790A (zh) 2023-03-16 2025-11-28 拜耳消费者护理股份有限公司 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
EP4520322A1 (en) * 2023-12-06 2025-03-12 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical compositions containing enzalutamide
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法
TR2024004340A1 (tr) * 2024-04-05 2025-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enzalutamidin katı dispersiyonu.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
ES2287971T3 (es) † 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
IN191496B (https=) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
PE20011184A1 (es) 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
CZ20032225A3 (cs) 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
SE0103424D0 (sv) † 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
BR0307515A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
JP2005523360A (ja) * 2002-04-18 2005-08-04 アベシア・リミテッド 共役分子の製造および製造において使用するための物質
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
AU2003209667A1 (en) * 2003-02-21 2004-09-09 Hetero Drugs Limited Bicalutamide polymorphs
EP1730516A1 (en) 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
WO2008110534A1 (en) 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
CN102083467B (zh) 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
MY172424A (en) † 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
DK2538785T3 (en) * 2010-02-24 2018-05-22 Medivation Prostate Therapeutics Llc Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
NZ602288A (en) * 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
EP2858985B1 (en) 2012-06-07 2018-04-18 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US9515365B2 (en) * 2012-08-10 2016-12-06 Keyssa, Inc. Dielectric coupling systems for EHF communications
KR20150053963A (ko) 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP7172997B2 (ja) 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
WO2021064123A1 (en) 2019-10-03 2021-04-08 Synthon B.V. Pharmaceutical composition comprising enzalutamide

Also Published As

Publication number Publication date
US20230210778A1 (en) 2023-07-06
DK3725778T3 (da) 2021-09-20
PL3725778T5 (pl) 2026-03-23
US20200060976A1 (en) 2020-02-27
KR20150082203A (ko) 2015-07-15
EA201991484A1 (ru) 2019-11-29
JP2019194262A (ja) 2019-11-07
EP3725778B2 (en) 2026-01-07
EP3725778A1 (en) 2020-10-21
TW201427659A (zh) 2014-07-16
AU2013315619B2 (en) 2018-02-08
JP6932746B2 (ja) 2021-09-08
US12502357B2 (en) 2025-12-23
MX2015003140A (es) 2015-12-16
HRP20211423T4 (hr) 2026-02-27
JP2021178871A (ja) 2021-11-18
PL3725778T3 (pl) 2021-12-20
CN105358535A (zh) 2016-02-24
HRP20211423T1 (hr) 2022-01-21
AU2018200316A1 (en) 2018-02-08
SI3725778T1 (sl) 2022-02-28
EP3971167A1 (en) 2022-03-23
WO2014043208A1 (en) 2014-03-20
CA2884795C (en) 2023-10-17
US20250090465A1 (en) 2025-03-20
EP3725778B1 (en) 2021-08-18
CN105358535B (zh) 2019-01-04
JP2018087206A (ja) 2018-06-07
IL237604A0 (en) 2015-04-30
FI3725778T4 (fi) 2026-03-11
EA033374B9 (ru) 2019-12-18
EP4450130A3 (en) 2025-01-08
JP6404217B2 (ja) 2018-10-10
EP4324527A3 (en) 2024-04-24
TWI673051B (zh) 2019-10-01
US20250049721A1 (en) 2025-02-13
US20140179749A1 (en) 2014-06-26
CA2884795A1 (en) 2014-03-20
ZA201501847B (en) 2016-01-27
MX2021000007A (es) 2021-03-09
US12447128B2 (en) 2025-10-21
US20170027910A1 (en) 2017-02-02
US20230122911A1 (en) 2023-04-20
AU2013315619A1 (en) 2015-04-30
CN109897004A (zh) 2019-06-18
EP4169908A1 (en) 2023-04-26
LT3725778T (lt) 2021-12-27
IN2015DN02875A (https=) 2015-09-11
HK1212701A1 (zh) 2016-06-17
ES2892029T3 (es) 2022-02-01
US20170224624A1 (en) 2017-08-10
PT3725778T (pt) 2021-09-22
UA117353C2 (uk) 2018-07-25
US11839689B2 (en) 2023-12-12
JP2016204392A (ja) 2016-12-08
ES2892029T5 (en) 2026-03-25
JP2015527411A (ja) 2015-09-17
PH12015500525A1 (en) 2015-05-04
EP4324527A2 (en) 2024-02-21
MX363974B (es) 2019-04-10
RS62676B2 (sr) 2026-03-31
KR102225416B1 (ko) 2021-03-09
DK3725778T4 (da) 2026-02-09
EP2895463A1 (en) 2015-07-22
MX2019003984A (es) 2019-08-12
SMT202100550T1 (it) 2022-01-10
CY1124729T1 (el) 2022-07-22
US20140378517A1 (en) 2014-12-25
US20190209476A1 (en) 2019-07-11
EP4450130A2 (en) 2024-10-23
EA201500314A1 (ru) 2015-12-30
HUE057701T2 (hu) 2022-05-28
US20140100256A1 (en) 2014-04-10
RS62676B1 (sr) 2021-12-31
EA033374B1 (ru) 2019-10-31
BR112015005432A2 (https=) 2017-09-05
BR112015005432B1 (pt) 2023-04-18

Similar Documents

Publication Publication Date Title
ZA201501847B (en) Formulations of enzalutamide
PL2877155T3 (pl) Formulacje opioidowe
ZA201407373B (en) Novel pharmaceutical formulations
SG11201500412TA (en) Vaccine compositions
SI2827862T1 (sl) Formulacije bendamustina
IL289157A (en) Opioid compounds
ZA201406082B (en) Use of ccr3-inhibitors
EP4342536C0 (en) BROMOCRIPTINE FORMULATIONS
ZA201306000B (en) Stable formulation
SG11201504134SA (en) External preparation
GB201501016D0 (en) Preparation of 18F-fluciclovine
IL217807A0 (en) Therapeutic compositions
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
GB201312378D0 (en) Structure of shoe
GB201210530D0 (en) Extended release formulations
PL2908859T3 (pl) Formulacje arypiprazolu
GB201206178D0 (en) Formulations
IL233879A0 (en) Dry powdered dnase i preparations
TWM433525U (en) Structure of calorifier
HUE036665T2 (hu) Dihidro-pirido-oxazin származék szilárd formái
GB201211247D0 (en) Improved formulation
GB201216165D0 (en) Virtues iBrush
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations